Head & neck · 2015
Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Levy Antonin, De Felice Francesca, Bellefqih Sara, Guigay Joël, Deutsch Eric, Nguyen France, Blanchard Pierre, Tao Yungan
Аннотация
BACKGROUND: The purpose of this study was to evaluate the tolerability of concurrent radiotherapy and cetuximab (bioradiotherapy [BRT]) after taxane-based induction chemotherapy in head and neck squamous cell carcinoma (HNSCC).
METHODS: One hundred four patients with HNSCC received BRT with (29%) or without (71%) prior taxane-based induction chemotherapy.
RESULTS: Radiodermatitis (97%) and skin rash (65%) occurred frequently, but there was no difference of occurrence or the grade of the rash observed in the 2 populations. However, patients receiving taxane-based induction chemotherapy had a less severe rash as compared with patients without induction chemotherapy. Mucositis and dysphagia were frequent and comparable in the 2 groups. The occurrence of a skin rash (at any grade) did not predict an increased overall survival (OS) in the overall population, but it was associated with an improved 3-year OS in patients receiving taxane-based induction chemotherapy. OS was not influenced by the skin rash grade in the overall population of the 2 treatment subgroups.
CONCLUSION: Taxane-based induction chemotherapy did not increase the rate of cetuximab-related toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: E905-E910, 2016.
METHODS: One hundred four patients with HNSCC received BRT with (29%) or without (71%) prior taxane-based induction chemotherapy.
RESULTS: Radiodermatitis (97%) and skin rash (65%) occurred frequently, but there was no difference of occurrence or the grade of the rash observed in the 2 populations. However, patients receiving taxane-based induction chemotherapy had a less severe rash as compared with patients without induction chemotherapy. Mucositis and dysphagia were frequent and comparable in the 2 groups. The occurrence of a skin rash (at any grade) did not predict an increased overall survival (OS) in the overall population, but it was associated with an improved 3-year OS in patients receiving taxane-based induction chemotherapy. OS was not influenced by the skin rash grade in the overall population of the 2 treatment subgroups.
CONCLUSION: Taxane-based induction chemotherapy did not increase the rate of cetuximab-related toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: E905-E910, 2016.